Compare Roivant Sciences Ltd. Common Shares (ROIV) vs Somnigroup International Inc. Common Stock (SGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roivant Sciences Ltd. Common Shares vs Somnigroup International Inc. Common Stock — how do they compare? Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B), while Somnigroup International Inc. Common Stock trades at $62.78 (market cap $14.48B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Somnigroup International Inc. Common Stock pays a 1.08% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roivant Sciences Ltd. Common Shares for 3 Days and Somnigroup International Inc. Common Stock for 0 Days on average.
| ROIV | SGI | |
|---|---|---|
Market Cap | $24.99B | $14.48B |
Volume | 4,711,562 | 1,734,399 |
Sector | Health | Consumer Cyclical |
52-Week High | $41.81 | $97.99 |
52-Week Low | $16.99 | $61.49 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $21.25B | $20.78B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.
SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →About Somnigroup International Inc. Common Stock
Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.
Read more on SGI →
